Williet, N., Saint, A., Pointet, A., Tougeron, D., Pernot, S., Pozet, A., . . . Taieb, J. (2019). Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: A comparative propensity score study. Therap Adv Gastroenterol.
Citación estilo ChicagoWilliet, Nicolas, et al. "Folfirinox Versus Gemcitabine/nab-paclitaxel As first-line Therapy in Patients With Metastatic Pancreatic Cancer: A Comparative propensity Score Study." Therap Adv Gastroenterol 2019.
Cita MLAWilliet, Nicolas, et al. "Folfirinox Versus Gemcitabine/nab-paclitaxel As first-line Therapy in Patients With Metastatic Pancreatic Cancer: A Comparative propensity Score Study." Therap Adv Gastroenterol 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.